Obesity: Key Pipeline Developments and Clinical Trial Insights - IQVIA
Obesity, linked to 5 million deaths globally, increases risks of T2DM, heart disease, and cancers. GLP1R agonists like semaglutide (WEGOVY) emerged as effective treatments, with tirzepatide (ZEPBOUND) and setmelanotide (IMCIVREE) also approved. The article updates on current obesity treatments and ongoing clinical trials.
Reference News
Obesity: Key Pipeline Developments and Clinical Trial Insights - IQVIA
Obesity, linked to 5 million deaths globally, increases risks of T2DM, heart disease, and cancers. GLP1R agonists like semaglutide (WEGOVY) emerged as effective treatments, with tirzepatide (ZEPBOUND) and setmelanotide (IMCIVREE) also approved. The article updates on current obesity treatments and ongoing clinical trials.